论文部分内容阅读
目的探讨雌激素受体(ER)与血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)中的表达及其与生物学行为的关系。方法76例临床资料完整的肺癌手术切除标本,采用免疫组化方法检测其中ER、VEGF及微血管密度(MVD)的表达情况。结果76例NSCLC的ER的阳性表达率为69.7%(53/76),VEGF的阳性表达率为48.7%(37/76)。临床分期低、无淋巴结转移和中高分化的ER表达要高于临床分期高、有淋巴结转移和低未分化的的肺癌组织,临床分期低、有淋巴结转移和低未分化的VEGF和MVD的表达要高于临床分期低、无淋巴结转移和中高分化的的肺癌组织,差异均具有统计学意义(P<0.05),并且ER的表达与VEGF和FⅧ的表达呈负相关。结论肺癌组织中ER、VEGF和MVD可能在非小细胞肺癌的发生、发展中共同起作用。联合检测可作为评价非小细胞肺癌恶性程度和预后的共同指标。
Objective To investigate the expression of estrogen receptor (ER) and vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) and its relationship with biological behavior. Methods Seventy-six patients with lung cancer were enrolled in this study. The expression of ER, VEGF and microvessel density (MVD) were detected by immunohistochemistry. Results The positive expression rate of ER in 76 cases of NSCLC was 69.7% (53/76), and the positive rate of VEGF was 48.7% (37/76). The expression of ER with low clinical stage, no lymph node metastasis and moderately well-differentiated was higher than those with high clinical stage, lymph node metastasis and low undifferentiated lung cancer, with low clinical stage, lymph node metastasis and poorly differentiated VEGF and MVD The difference was statistically significant (P <0.05), and the expression of ER was negatively correlated with the expression of VEGF and FⅧ in lung cancer tissues with low clinical stage, no lymph node metastasis and moderately differentiated lung cancer. Conclusion ER, VEGF and MVD in lung cancer may play a role in the development and progression of non-small cell lung cancer. Joint detection can be used as a common indicator of malignancy and prognosis of non-small cell lung cancer.